Transplantation and Cellular Therapy · 2022 · 19 citations · 59 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationTransplant ImmunologyVaccinologyChimeric Antigen Receptor T-cell TherapyImmunization PracticeImmunization SchedulesVaccinationVaccine EfficacyVaccine-preventable DiseasesCar T Cell TrialsCoronavirus VaccinesCovid-19 Vaccination PolicyHematopoietic Stem Cell Transplantation ImmunotherapySars-cov-2 InfectionVaccination In Transplant RecipientsVaccination Responses After TransplantViral Immune Responses
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. Not only are hematopoietic cell transplantation (HCT) and chimeric antigen receptor (CAR) T-cell recipients at greater risk for severe COVID-19 and COVID-19-related complications, but they also may experience suboptimal immune responses to currently available COVID-19 vaccines. Optimizing the use, timing, and number of doses of the COVID-19 vaccines in these patients may provide better protection against SARS-CoV-2 infection and better outcomes after infection. To this end, current guidelines for COVID-19 vaccination in HCT and CAR T-cell recipients from the American Society of Transplantation and Cellular Therapy Transplant Infectious Disease Special Interest Group and the American Society of Hematology are provided in a frequently asked questions format.
59
Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text